# Management of alopecia areata
Treatment intensity for alopecia areata is matched to disease severity measured by the Severity of Alopecia Tool (SALT) score, and SALT ≤20 is the agreed therapeutic goal for moderate-to-severe disease.[1](https://doi.org/10.1111/jdv.19768)
Treatment is stepped. For limited or mild disease, first-line options are potent topical corticosteroids, intralesional corticosteroid injections, or watchful waiting, depending on extent and patient preference.[2](https://doi.org/10.1093/bjd/ljaf452) • [3](https://www.actasdermo.org/es-consensus-document-on-clinical-management-articulo-S0001731026000190) For severe disease (SALT >50), oral [Janus kinase](https://www.edgepedia.org/janus-kinase) (JAK) inhibitors, baricitinib and ritlecitinib, are the drugs of choice, with deuruxolitinib an additional option.[4](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1846243/pdf) Contact immunotherapy, wigs, and camouflage fill specific roles where systemic therapy is declined, contraindicated, or unlikely to be acceptable to the patient.
| Fact | Detail |
|---|---|
| Therapeutic goal | SALT ≤20; switch or dose modification if not achieved within 24–36 weeks[1](https://doi.org/10.1111/jdv.19768) |
| Spontaneous remission | ~40% of single-patch episodes remit within 6 months; in severe AA spontaneous recovery is under 7%[5](https://doi.org/10.1111/ajd.14597) • [6](http://www.anaisdedermatologia.org.br/en-ii-consensus-brazilian-society-dermatology-articulo-S0365059624002277) |
| Baricitinib efficacy | 38.8% of patients on 4 mg/day reached SALT ≤20 at week 36 vs 6.2% on placebo (BRAVE-AA pooled, n=1,200)[1](https://doi.org/10.1111/jdv.19768) |
| Ritlecitinib efficacy | SALT ≤20 in 43% at 48 weeks on 50 mg/day[5](https://doi.org/10.1111/ajd.14597) |
| Relapse after stopping | Overall relapse can reach 85%; about one-fifth of patients stay in remission after withdrawal[1](https://doi.org/10.1111/jdv.19768) • [5](https://doi.org/10.1111/ajd.14597) |
| Boxed warning | Serious infections, mortality, malignancy, major adverse cardiovascular events, thrombosis (FDA, JAK inhibitors)[7](https://www.ncbi.nlm.nih.gov/books/NBK537000/) |
| Cost | £949.41 for 30 ritlecitinib capsules (UK NHS); baricitinib cost per 'cure' $2,695.87 AUD per month in Australia[5](https://doi.org/10.1111/ajd.14597) |
| UK funding | Of three licensed JAK inhibitors, only ritlecitinib is NHS-funded (NICE TA958)[8](https://www.dovepress.com/real-world-evidence-in-alopecia-areata-current-management-emerging-the-peer-reviewed-fulltext-article-JIR) |
## Watchful waiting and spontaneous remission
A significant fraction of mild AA resolves on its own. [The Australian](https://www.edgepedia.org/the-australian) consensus reports that roughly 40% of episodes present as a single patch achieving spontaneous complete durable remission within 6 months, while the Brazilian consensus puts the figure at about 50% within six months and 70% within the first year; a review of international guidelines gives 34–50% recovery within one year of onset.[5](https://doi.org/10.1111/ajd.14597) • [6](http://www.anaisdedermatologia.org.br/en-ii-consensus-brazilian-society-dermatology-articulo-S0365059624002277) • [9](https://doi.org/10.3390/ijms26178632) The Cochrane network meta-analysis concludes that most cases remit spontaneously and that not treating may be appropriate when consistent with patient wishes.[10](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013719.pub2/abstract?cookiesEnabled)
This applies to limited disease only. In severe AA spontaneous recovery falls below 7%, and in placebo arms of severe-disease trials regrowth of at least 50% of scalp hair ranged from 0% to 16.7%.[6](http://www.anaisdedermatologia.org.br/en-ii-consensus-brazilian-society-dermatology-articulo-S0365059624002277) • [1](https://doi.org/10.1111/jdv.19768) Wait-and-see is therefore not advised for patients who qualify for systemic therapy. Roughly 7% of all patients progress to alopecia totalis or universalis, with worse prognosis associated with childhood onset, duration over 12 months, nail involvement, atopy, associated autoimmune disease, and family history.[6](http://www.anaisdedermatologia.org.br/en-ii-consensus-brazilian-society-dermatology-articulo-S0365059624002277)
## Corticosteroids: topical and intralesional
**Topical corticosteroids** are the guideline first-line treatment for scalp hair loss in primary or secondary care: the British Association of Dermatologists (BAD) 2025 living guideline recommends a potent or very potent topical corticosteroid once daily for 3–6 months.[2](https://doi.org/10.1093/bjd/ljaf452) In children and young people, a 6-weeks-on/6-weeks-off regimen followed by another 6-week treatment cycle is suggested.[2](https://doi.org/10.1093/bjd/ljaf452) The Merck Manual describes potent agents such as clobetasol propionate 0.05% foam, gel, or ointment twice daily for about 4 weeks.[11](https://www.merckmanuals.com/professional/dermatologic-disorders/hair-disorders/alopecia-areata)
**Intralesional corticosteroid injections** deliver triamcinolone acetonide directly into affected patches. The standard regimen is 0.1 to 3 mL at a concentration of 2.5 to 5 mg/mL, repeated every 4 to 8 weeks for small lesions.[11](https://www.merckmanuals.com/professional/dermatologic-disorders/hair-disorders/alopecia-areata) The Brazilian consensus names intralesional corticosteroids the treatment of choice for mild cases; the Spanish consensus recommends triamcinolone over betamethasone because of greater efficacy with a similar safety profile.[6](http://www.anaisdedermatologia.org.br/en-ii-consensus-brazilian-society-dermatology-articulo-S0365059624002277) • [3](https://www.actasdermo.org/es-consensus-document-on-clinical-management-articulo-S0001731026000190) The sources reviewed do not provide a quantified regrowth rate for injection monotherapy, so expectations should be framed as clinically meaningful regrowth in patchy disease rather than a specific percentage.
For non-responders, the Spanish consensus recommends weekly systemic corticosteroid pulse therapy, for example dexamethasone 0.1 mg/kg two days per week, with full-dose systemic corticosteroids limited to 3–6 months followed by tapering.[3](https://www.actasdermo.org/es-consensus-document-on-clinical-management-articulo-S0001731026000190)
## JAK inhibitors
**Mechanism and approvals.** [Baricitinib](https://www.edgepedia.org/baricitinib) (Olumiant), a JAK1/2 inhibitor, was the first medication approved by both the EMA and FDA for severe AA in adults aged 18 or older.[1](https://doi.org/10.1111/jdv.19768) [Ritlecitinib](https://www.edgepedia.org/ritlecitinib) (Litfulo) is a selective dual JAK3 and TEC inhibitor approved by the FDA and EMA for adults and adolescents aged 12 and over.[1](https://doi.org/10.1111/jdv.19768) Deuruxolitinib, a JAK1/JAK2 inhibitor, received FDA approval for adults with severe AA in July 2024.[12](https://link.springer.com/article/10.1007/s40257-026-01060-z) These three are the only FDA-approved treatments for severe AA.[13](https://jddonline.com/articles/efficacy-safety-real-world-aspects-of-janus-kinase-inhibitors-treat-patients-with-alopecia-areata-S1545961626P9292X)
**Efficacy.** In the pooled BRAVE-AA1 and BRAVE-AA2 trials of 1,200 patients with SALT >50, 38.8% on baricitinib 4 mg/day achieved SALT ≤20 at week 36 versus 22.8% on 2 mg/day and 6.2% on placebo.[1](https://doi.org/10.1111/jdv.19768) The Australian consensus cites a published baricitinib 4 mg SALT ≤20 response of 51.9% at 36 weeks, and 43% at 48 weeks for ritlecitinib 50 mg daily.[5](https://doi.org/10.1111/ajd.14597) In ritlecitinib's phase 2b-3 trial at week 24, SALT ≤20 was reached by 31% of the 200 mg/50 mg group, 23% of the 50 mg group, and 2% on placebo.[1](https://doi.org/10.1111/jdv.19768) Cochrane grades the baricitinib regrowth evidence as high certainty (RR 7.54 for short-term regrowth ≥75%, 95% CI 3.90–14.58).[10](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013719.pub2/abstract?cookiesEnabled) Overall, meaningful regrowth occurs in over two-thirds of treated chronic severe AA patients, and approximately 90% of responders maintain response out to 152 weeks.[5](https://doi.org/10.1111/ajd.14597) Response rates are comparable across baseline SALT 20–95, so severity alone does not predict benefit within the systemic-therapy range.[5](https://doi.org/10.1111/ajd.14597)
**Dosing and monitoring.** Baricitinib is initiated at 2 mg/day with escalation to 4 mg/day after 3 months if response is inadequate, and discontinued if no improvement occurs after 6 months.[7](https://www.ncbi.nlm.nih.gov/books/NBK537000/) The EMA-approved ritlecitinib dose is 50 mg/day, with laboratory monitoring of platelet and lymphocyte counts.[1](https://doi.org/10.1111/jdv.19768) The Spanish consensus recommends a pre-treatment workup of complete blood count, liver and renal biochemistry, lipid levels, hepatitis B/C and HIV serologies, latent tuberculosis screening, and pregnancy testing; live attenuated vaccines should be avoided during treatment and within 4 weeks before starting.[3](https://www.actasdermo.org/es-consensus-document-on-clinical-management-articulo-S0001731026000190) The most common side effects are headache and acne, with no increase in serious adverse events.[1](https://doi.org/10.1111/jdv.19768)
**Warnings and restrictions.** US labeling carries a boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis.[7](https://www.ncbi.nlm.nih.gov/books/NBK537000/) In 2023 the EMA recommended JAK inhibitors be used only where no suitable alternatives exist for patients aged 65 and over, long-time smokers, people with cardiovascular disease or risk factors, and those with malignancy risk factors.[1](https://doi.org/10.1111/jdv.19768)
**Stopping treatment.** Relapse is the central limitation. The overall relapse rate in AA can reach 85%, and a next course of treatment may be less effective: when ritlecitinib responders were switched to placebo and then re-treated on relapse, only 57% responded to the second course.[1](https://doi.org/10.1111/jdv.19768) Conversely, about one-fifth of patients remain in remission after withdrawal, so the Australian consensus suggests discontinuation may be considered after 6–12 months of achieved target response.[5](https://doi.org/10.1111/ajd.14597) The Spanish consensus advises maintaining treatment for nine months to evaluate effectiveness and notes that relapses are frequent after dose reduction or discontinuation.[3](https://www.actasdermo.org/es-consensus-document-on-clinical-management-articulo-S0001731026000190) After failure of one JAK inhibitor, switching to another, including off-label options, may be considered.[3](https://www.actasdermo.org/es-consensus-document-on-clinical-management-articulo-S0001731026000190)
## Contact immunotherapy (DPCP and SADBE)
Contact immunotherapy on the scalp uses sensitizers such as diphenylcyclopropenone (DPCP) or squaric acid dibutyl ester (SADBE).[9](https://doi.org/10.3390/ijms26178632) A meta-analysis found hair regrowth in 74.6% of patients with patchy AA versus 54.4% of those with alopecia totalis or universalis, and recurrence of 38.2% with maintenance treatment versus 49% without.[7](https://www.ncbi.nlm.nih.gov/books/NBK537000/)
How it ranks against JAK inhibitors is disputed. One network meta-analysis of severe AA ranked efficacy by SUCRA as oral dexamethasone (95.9%) > DPCP (74.5%) > ritlecitinib (62.6%) > baricitinib (46.9%) > SADBE (20.1%) > placebo, but for tolerability DPCP ranked last (3.8%) and the authors noted some DPCP and dexamethasone adverse events were intolerable while JAK-inhibitor events were more manageable.[14](https://link.springer.com/article/10.1007/s00403-024-03177-9) Cochrane, by contrast, found only very-low-certainty evidence for DPCP/SADBE versus placebo (RR 1.16, 95% CI 0.79–1.71) against high-certainty evidence for baricitinib, so the apparent superiority of DPCP rests on weaker data.[10](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013719.pub2/abstract?cookiesEnabled)
Guidelines also diverge on its place: Saudi experts recommend DPCP with SADBE as an alternative, the Australian consensus proposes it for extensive stable disease, while the European consensus does not recommend it.[9](https://doi.org/10.3390/ijms26178632) The Spanish consensus positions it as second-line for patients with contraindications to, or refusal of, systemic therapy.[3](https://www.actasdermo.org/es-consensus-document-on-clinical-management-articulo-S0001731026000190) The international ACE consensus recommends children with [alopecia universalis](https://www.edgepedia.org/alopecia-universalis), totalis, or ophiasis be offered contact immunotherapy before systemic therapy is considered, and that it be continued until complete regrowth rather than stopped at first sign of regrowth.[15](https://www.sinclairdermatology.com.au/wp-content/uploads/2020/06/202007-JAAD-The-Alopecia-Areata-Consensus-of-Experts-ACE-study.pdf)
## Adjuncts, wigs, and camouflage
**Minoxidil.** Cochrane rates the evidence for topical minoxidil 1–2% as very low certainty (RR 2.31, 95% CI 1.34–3.96 versus placebo), and adjunctive topical or oral minoxidil is often used to support regrowth and reduce relapse risk although the supporting evidence is weak.[10](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013719.pub2/abstract?cookiesEnabled) • [8](https://www.dovepress.com/real-world-evidence-in-alopecia-areata-current-management-emerging-the-peer-reviewed-fulltext-article-JIR) The Spanish consensus notes oral minoxidil may be combined with intralesional or topical treatment to improve hair density during regrowth.[3](https://www.actasdermo.org/es-consensus-document-on-clinical-management-articulo-S0001731026000190)
**Wigs and camouflage** are guideline-endorsed management, not fallbacks. The BAD living guideline recommends offering wigs, and toppers, to people whose quality of life is likely to benefit, suggesting a minimum of two synthetic wigs or one human hair wig per year (if meeting clinical criteria) per the NHS Wig Provision charter.[2](https://doi.org/10.1093/bjd/ljaf452) Patients are also advised to explore hats, scarves, turbans, makeup, hair fibers, powders, sprays, permanent makeup, and skin micropigmentation.[2](https://doi.org/10.1093/bjd/ljaf452) [Reimbursement](https://www.edgepedia.org/reimbursement) outside the UK NHS is not documented in the sources reviewed.
## References
1. European expert consensus statement on the systemic treatment of alopecia areata. https://doi.org/10.1111/jdv.19768
2. British Association of Dermatologists living guideline for managing people with alopecia areata 2025. https://doi.org/10.1093/bjd/ljaf452
3. Consensus Document on the Clinical Management of Alopecia Areata, Spanish Academy of Dermatology and Venereology. https://www.actasdermo.org/es-consensus-document-on-clinical-management-articulo-S0001731026000190
4. A consensus-based treatment algorithm for alopecia areata in adolescents and adults. https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1846243/pdf
5. Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement. https://doi.org/10.1111/ajd.14597
6. II Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata. http://www.anaisdedermatologia.org.br/en-ii-consensus-brazilian-society-dermatology-articulo-S0365059624002277
7. Alopecia Areata. StatPearls, NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK537000/
8. Real-world evidence in alopecia areata: findings and future directions. https://www.dovepress.com/real-world-evidence-in-alopecia-areata-current-management-emerging-the-peer-reviewed-fulltext-article-JIR
9. Comparison of Current International Guidelines for the Management of Alopecia Areata. https://doi.org/10.3390/ijms26178632
10. Treatments for alopecia areata: a network meta-analysis (Cochrane). https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013719.pub2/abstract?cookiesEnabled
11. Alopecia Areata. Merck Manual Professional Edition. https://www.merckmanuals.com/professional/dermatologic-disorders/hair-disorders/alopecia-areata
12. Efficacy and Safety of Oral Janus Kinase Inhibitors in Adults and Adolescents with Alopecia Areata. https://link.springer.com/article/10.1007/s40257-026-01060-z
13. Efficacy, Safety, and Real-World Aspects of Janus Kinase Inhibitors to Treat Patients With Alopecia Areata. https://jddonline.com/articles/efficacy-safety-real-world-aspects-of-janus-kinase-inhibitors-treat-patients-with-alopecia-areata-S1545961626P9292X
14. Comparative efficacy and safety of systemic steroids, oral JAK inhibitors and contact immunotherapy in severe alopecia areata. https://link.springer.com/article/10.1007/s00403-024-03177-9
15. The Alopecia Areata Consensus of Experts (ACE) study. https://www.sinclairdermatology.com.au/wp-content/uploads/2020/06/202007-JAAD-The-Alopecia-Areata-Consensus-of-Experts-ACE-study.pdf
---
*Topic: Encyclopedia › Life and health › Human health and medicine › Diseases and injuries › Skin and musculoskeletal conditions › Hair and nail disorders › Alopecia areata › Management of alopecia areata*
*Initially written Sep 17, 2026 · Edited: Oct 11, 2026; Oct 15, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license